$33.0M
The Kent biotechnology spinout raised the capital from backers including XGEN Venture and the British Business Bank to push its lead treatment into clinical evaluation.
"Refractory epilepsy is a devastating condition causing unpredictable and life-threatening seizures, and affecting millions of patients worldwide. Our novel gene therapy EPY201 delivered directly to the seizure focus has the potential to stop seizures with a single, minimally invasive administration. In doing so, it will change the way refractory epilepsy has been treated for decades. We are proud to have the support of such high calibre investors as we progress into clinical trials."
E
EpilepsyGTx—Kent, UKXGEN Venture + 1 other
